Cargando…

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models

Pheochromocytomas and paragangliomas (PCCs/PGLs) are catecholamine-producing tumors. In inoperable and metastatic cases, somatostatin type 2 receptor (SSTR2) expression allows for peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE. Insufficient receptor levels, however, limit treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ullrich, Martin, Richter, Susan, Liers, Josephine, Drukewitz, Stephan, Friedemann, Markus, Kotzerke, Jörg, Ziegler, Christian G., Nölting, Svenja, Kopka, Klaus, Pietzsch, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800739/ https://www.ncbi.nlm.nih.gov/pubmed/36593963 http://dx.doi.org/10.7150/thno.77918

Ejemplares similares

Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine
por: Nölting, Svenja, et al.
Publicado: (2019)

Strain-specific metastatic phenotypes in pheochromocytoma allograft mice
por: Ullrich, Martin, et al.
Publicado: (2018)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses
por: Fischer, Alessa, et al.
Publicado: (2023)

Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model
por: Helm, Jana, et al.
Publicado: (2022)

Cyclotron-Based Production of (67)Cu for Radionuclide Theranostics via the (70)Zn(p,α)(67)Cu Reaction
por: Brühlmann, Santiago Andrés, et al.
Publicado: (2023)

Case report: Incidentally discovered case of pheochromocytoma as a cause of long COVID-19 syndrome
por: Ziegler, Christian G., et al.
Publicado: (2022)

Efficient Production of the PET Radionuclide (133)La for Theranostic Purposes in Targeted Alpha Therapy Using the (134)Ba(p,2n)(133)La Reaction
por: Brühlmann, Santiago Andrés, et al.
Publicado: (2022)

HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models
por: Seifert, Verena, et al.
Publicado: (2021)

Subcellular Targeting of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2018)

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2017)

Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background
por: Ullrich, Martin, et al.
Publicado: (2019)

Somatostatin Receptor Based Imaging and Radionuclide Therapy
por: Xu, Caiyun, et al.
Publicado: (2015)

Somatostatin Receptor Theranostics for Refractory Meningiomas
por: Salgues, Betty, et al.
Publicado: (2022)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells
por: Brandt, Florian, et al.
Publicado: (2022)

Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics
por: Gilpin, Ian Moore F., et al.
Publicado: (2021)

Sub‐10 nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha Therapy
por: Reissig, Falco, et al.
Publicado: (2020)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

Comparative Saturation Binding Analysis of (64)Cu-Labeled Somatostatin Analogues Using Cell Homogenates and Intact Cells
por: Ullrich, Martin, et al.
Publicado: (2023)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Somatostatin-secreting Pheochromocytoma Mimicking Insulin-dependent Diabetes Mellitus
por: Hirai, Hiroyuki, et al.
Publicado: (2016)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED
por: Formento Cavaiera, R, et al.
Publicado: (2020)

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014)

Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging †
por: Reissig, Falco, et al.
Publicado: (2020)

Cyclotron-based production of the theranostic radionuclides $^{67}$Cu and $^{47}$Sc
por: Pupillo, G, et al.
Publicado: (2019)

Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide (47)Sc
por: Loveless, C. Shaun, et al.
Publicado: (2019)

Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry
por: Marquis, H., et al.
Publicado: (2021)

Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer
por: Li, Rou, et al.
Publicado: (2021)

Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements
por: Mikolajczak, R., et al.
Publicado: (2021)

Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells
por: Bechmann, Nicole, et al.
Publicado: (2019)

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014)

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
por: Werner, Rudolf A., et al.
Publicado: (2016)

Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma
por: Rossini, Alessandro, et al.
Publicado: (2019)

Molecular imaging using the theranostic agent (197(m))Hg: phantom measurements and Monte Carlo simulations
por: Freudenberg, Robert, et al.
Publicado: (2018)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Oligonucleotide-Functionalized Gold Nanoparticles for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2021)

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review
por: Hussain, Mazhar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n7qverr2mjcocrqfqjakd52eil